Overview

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

Status:
Recruiting

Trial end date:
2021-11-17

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.

Phase:

Phase 3

Details

Lead Sponsor:

Atea Pharmaceuticals, Inc.

Collaborator:

Hoffmann-La Roche